Oncology News | pharmaphorum

News

PARP rivals close in on AZ and Merck's market leading Lynpar...

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market s

News

UK's Pheon is latest kid on the block in ADC sector

There's a new player on the antibody-drug conjugate (ADC) scene.

News

Roche puts $70m into ArsenalBio's programmable T-cell platfo...

Roche's Genentech division has formed an R&D partnership with Arsenal Biosciences focusing on developing and refining the biotech's programmable T cell-based therapies platform.

News

Daiichi Sankyo grabs first approval for blood cancer drug Ez...

Japan's Daiichi Sankyo has claimed its first worldwide approval for Ezharmia, a first-in-class dual EZH1 and EZH2 inhibitor for the treatment of patients with relapsed or refractory adult T

News

FDA panel shoots down Spectrum, Oncopeptides' cancer drugs

Chances of FDA approval for Spectrum Pharma's lung cancer candidate poziotinib and Oncopeptides' Pepaxto for multiple myeloma have taken a dive, after the regulator's expert advisors voted

News

Routine NHS access to Ibrance assured with new NICE guidance

Thousands of patients with a particular form of breast cancer in England and Wales can be confident they will continue to have access to Pfizer's targeted therapy Ibrance, thanks to new gui

PARP rivals close in on AZ and Merck's market leading Lynpar...

UK's Pheon is latest kid on the block in ADC sector

Roche puts $70m into ArsenalBio's programmable T-cell platfo...

Daiichi Sankyo grabs first approval for blood cancer drug Ez...

FDA panel shoots down Spectrum, Oncopeptides' cancer drugs

Routine NHS access to Ibrance assured with new NICE guidance

Amazon puts $100m into global health drive

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks